Protein kinase conjugates and inhibitors
The invention relates to protein conjugates that contain a protein kinase containing a cysteine residue in the ATP binding site and an inhibitor that is covalently and irreversibly bonded to said cysteine residue, such that the activity of the protein kinase is irreversibly inhibited. The invention also relates to compounds that irreversibly inhibit protein kinases.
1. A compound of formula XIII-b:
or a pharmaceutically acceptable salt thereof, wherein
Ra, Rb, Rc and Rd are independently selected from R, OR, halogen, —CN, C≡C—R, —NRxRy, and C(O)NHRz;
each R, Rx and Ry is independently hydrogen, lower alkyl, lower haloalkyl, or lower cycloalkyl;
each Rz is independently hydrogen, aliphatic, or aryl;
R 2 is hydrogen, optionally substituted aryl, or optionally substituted heteroaryl;
X is a bond or a bivalent C 1 -C 6 saturated or unsaturated, straight or branched hydrocarbon chain wherein optionally one, two or three methylene units of the hydrocarbon chain are independently replaced by —NR—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —S—, —SO—, —SO 2 —, —C(═S)—, —C(═NR)—, —N═N—, or —C(═N 2 )—;
Ring A is a 4-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aryl ring containing 0-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
R 1 is -L-Y;
L is a covalent bond or a bivalent C 1-8 saturated or unsaturated, straight or branched hydrocarbon chain, wherein one, two, or three methylene units of L are optionally and independently replaced by cyclopropylene, —NR—, —N(R)C(O)—, —C(O)N(R)—, —N(R)SO 2 —, —SO 2 N(R)—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —S—, —SO—, —SO 2 —, —C(═S)—, —C(═NR)—, —N═N—, or —C(═N 2 )—;
Y is hydrogen, nitrile, C 1-6 aliphatic optionally substituted with one or more OH, NRxRy, oxo, halogen, NO 2 , or CN, or a 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein said ring is substituted with 1-4 R e groups; and
each R e is independently selected from -Q-Z, OH, oxo, NO 2 , CN, a suitable leaving group, or a C 1-6 aliphatic optionally substituted with oxo, halogen, NO 2 , or CN, wherein:
Q is a covalent bond or a bivalent C 1-6 saturated or unsaturated, straight or branched hydrocarbon chain, wherein one or two methylene units of Q are optionally and independently replaced by —N(R)—, —S—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —SO—, —SO 2 —, —N(R)C(O)—, —C(O)N(R)—, —N(R)SO 2 —, or —SO 2 N(R)—; and
Z is hydrogen or C 1-6 aliphatic optionally substituted with oxo, halogen, NO 2 , or CN.